Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Cantor Fitzgerald
Teva
US Department of Justice
Daiichi Sankyo
Harvard Business School
Covington
Dow
Cerilliant

Generated: April 25, 2018

DrugPatentWatch Database Preview

Dasabuvir sodium; ombitasvir; paritaprevir; ritonavir - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir and what is the scope of dasabuvir sodium; ombitasvir; paritaprevir; ritonavir freedom to operate?

Dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. There are nineteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dasabuvir sodium; ombitasvir; paritaprevir; ritonavir has five hundred and sixteen patent family members in fifty-one countries.

One supplier is listed for this compound.
Summary for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
International Patents:516
US Patents:19
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 3,222
Drug Prices:see low prices
DailyMed Link:dasabuvir sodium; ombitasvir; paritaprevir; ritonavir at DailyMed

US Patents and Regulatory Information for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,674,112 Polymorph of a pharmaceutical ➤ Try a Free Trial
8,937,150 Anti-viral compounds ➤ Try a Free Trial
8,716,454 Solid compositions ➤ Try a Free Trial
9,452,194 Methods for treating HCV ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0731 Netherlands ➤ Try a Free Trial PRODUCT NAME: OMBITASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119
0730 Netherlands ➤ Try a Free Trial PRODUCT NAME: PARITAPREVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119
667 Luxembourg ➤ Try a Free Trial PRODUCT NAME: PARITAPREVIR, OU UN SEL OU ESTER PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX). FIRST REGISTRATION: 20150119
2368890/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
AstraZeneca
Farmers Insurance
Boehringer Ingelheim
Teva
Colorcon
Citi
QuintilesIMS
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.